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Abstract   26 
Background: Alcoholic liver disease (ALD) is a leading cause of liver cirrhosis, liver cancer 27 
and related mortality. The endocannabinoid system contributes to the development of chronic 28 
liver diseases, where cannabinoid receptor 2 (CB2) has been shown to have a protecting role. 29 
Thus, here we investigated how CB2 agonism by 4’-O-methylhonokiol (MHK), a biphenyl 30 
from Magnolia grandiflora, affects chronic alcohol-induced liver fibrosis and damage in 31 
mice. 32 
Methods: A combination of alcohol (10% vol/vol) and CCl4 (1ml/kg) was applied to 33 
C57Bl/6 mice for 5 weeks. MHK (5mg/kg) was administered daily. Liver damage was 34 
assessed by serum AST and ALT levels, histology, gene and protein expression. 35 
Endocannabinoids (ECs) and related lipid-derivatives were measured by liquid 36 
chromatography and mass spectrometry (LC-MS) in liver tissues. In vitro, MHK was studied 37 
in TGFβ1-activated hepatic stellate cells (HSC). 38 
Results: MHK treatment alleviated hepatic fibrosis, paralleled by induced expression of 39 
matrix metalloproteinases (MMP) -2, -3, -9 and -13, and downregulation of CB1 mRNA. 40 
Necrotic lesions and hepatic inflammation were moderately improved, while IL-10 mRNA 41 
increased and IFNγ, Mcl-1, JNK1 and RIPK1 normalized by MHK. Hepatic levels of 42 
anandamide (AEA) and related N-acetylethanolamines (NAEs) were elevated in MHK group, 43 
whereas fatty acid synthase and diacylglycerol O-acyltransferase 2 expression reduced. In 44 
vitro, MHK prevented HSC activation and induced apoptosis via induction of bak1 and bcl-2. 45 
Conclusions: MHK revealed hepatoprotective effects during alcohol-induced liver damage 46 
through the induction of MMPs, AEA and NAEs, and prevention of HSC activation, 47 
indicating MHK as a potent therapeutic for liver fibrosis and ALD. 48 
 49 
Keywords: alcohol, liver, cannabinoids, methylhonokiol, therapy   50 
51 
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INTRODUCTION 52 
Excess alcohol consumption is the most frequent cause of liver cirrhosis worldwide, and in 53 
2010, alcoholic liver cirrhosis was responsible for 493,300 deaths (47.9% of all liver cirrhosis 54 
deaths), representing 0.9% of all deaths regardless the cause (1). Moreover, alcoholic 55 
cirrhosis is the second most common indication for liver transplantation, accounting for 56 
approximately 40% of all primary liver transplants in Europe and about 25% in the United 57 
States (2). Despite this huge burden of disease, no effective pharmacological treatment for 58 
alcoholic liver disease (ALD) is approved, and drug interventions are primarily focused on 59 
achieving abstinence or risk reduction by decreasing alcohol consumption (3). Hence, novel 60 
therapeutic targets are clearly needed to specifically treat established ALD. 61 
Mounting evidence indicate that the endocannabinoid system (ECS) plays an important role 62 
in various liver diseases including viral hepatitis, non-alcoholic fatty liver disease (NAFLD), 63 
ALD, hepatic encephalopathy and autoimmune hepatitis (4). In particular, upregulation of 64 
cannabinoid receptors (CB) 1 and 2 in mostly all cronic liver diseases, cirrhosis and related 65 
disturbances were convincingly demonstrated, leading to the intriguing therapeutic concept of 66 
functional antagonism of these receptors in liver pathophysiology, with CB1 promoting and 67 
CB2 protecting from liver damage (5, 6) (7). Thus, in CB1−/− and CB2-/- mice, deletion of 68 
CB1 improved hepatic fibrosis and steatosis induced by carbon tetrachloride or high-fat-diet, 69 
whereas the lack of CB2 increased collagen deposition, liver fat and inflammation (8, 9). In 70 
experimental alcoholic models the CB2 agonist JWH-133 showed protective effects, as 71 
reflected by improved hepatic fibrosis, steatosis, inflammation and liver regeneration (10-12). 72 
Similarly, another CB2 agonist HU-308 alleviated tissue injury, decreased inflammatory cell 73 
infiltration and apoptosis during ischemia reperfusion (12).  74 
As a traditional medicine, Magnolia extracts has been used to treat gastrointestinal, anxiety 75 
and allergic diseases in Asian countries for several centuries (13-15). Honokiol, magnolol, 76 
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and 4’-O-methylhonokiol (MHK) are considered the major bioactive constituents 77 
of Magnolia grandiflora L. Although the structural similarity, MHK is the only compound 78 
which showed significant bioactive properties on the ECS as a CB2 receptor agonist and 79 
COX-2 substrate specific inhibitor for EC oxygenation (16-18). Recent studies revealed that 80 
magnolol and honokiol positively affect body fat accumulation and insulin resistance in high-81 
fat diet (HFD)-fed mice (19, 20), as well as improved fasting and plasma insulin levels in a 82 
type 2 diabetic model, alleviated hepatic oxidative damage, hyperglycemia and hyperlipemia 83 
(21-23). Also, honokiol was found to induce apoptotic death in activated rat HSCs suggesting 84 
an antifibrotic effect, while there was no such effect on hepatocytes (24). Magnolia 85 
officinalis extracts showed beneficial effects on hepatic lipid accumulation, inflammation, 86 
oxidative stress, and apoptosis in a HFD-induced obese mouse model (25-27). M. 87 
officinalis treatment of the rats on alcohol diet completely normalized serum liver enzyme 88 
levels, reversed steatosis, and completely inhibited the increased maturation of sterol 89 
regulatory element-binding protein-1c (SREBP1c) in the liver (28). Thus, Magnolia extracts 90 
seem to be promising candidates for ALD therapy. Here, we studied the therapeutic potential 91 
of MHK, a pure bioactive component of M. grandiflora and M. virginiana, in a murine model 92 
of alcohol-induced liver damage and accompanying fibrosis. 93 
 94 
  95 
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MATERIAL AND METHODS 96 
Materials 97 
The procedure of isolation and purification of 4’-O-Methylhonokiol is described in details by 98 
A. Chicca et al. in (18). 99 
 100 
Animals 101 
Male C57Bl/6 mice, 10 weeks age (20-25g) were obtained from Charles River, Sulzfeld, 102 
Germany, and kept under a 12h light–dark cycle with free access to rat chow (Provimi Kliba 103 
AG, Kaiseraugst, Switzerland) and water ad libitum. Animal experiment and all experimental 104 
protocols were approved by the research animal ethics committee and by the local board on 105 
animal care and experimentation of Canton Bern and were performed according to 106 
international guidelines concerning the conduct of animal experimentation.  107 
 108 
Cells 109 
Human hepatic stellate cells (HSC; ScienCell Research Laboratories, Carlsbad, CA) were 110 
cultured in Dulbecco’s modified Eagle's medium (DMEM), containing 10% FBS, 2 mM 111 
glutamine, 100 U/mL penicillin and 100 U/mL streptomycin. Cells were maintained at 37 °C 112 
in 5% CO2 humidified atmosphere. Cells were seeded onto 12-well plates and after reaching 113 
semi-confluent state starved in serum-free medium for next 24h. Treatment with 1-10µM 114 
MHK was performed for 6–24h in a complete serum-free medium.   115 
 116 
In vivo model of liver injury and treatment 117 
Liver fibrosis was induced in male adult C57Bl6 mice by chronic administration of 118 
combination of 10% (vol/vol) alcohol (EtOH) in sweetened drinking water (5% sucrose) 119 
daily and CCl4 (1ml/kg, 1:10 in corn oil), by intraperitoneal injections (i.p.), 2x weekly. This 120 
Patsenker et al.                                                                                            MHK in alcohol-induced liver damage 
 6
model replicates the “multiple hits” model, where CCl4 is used as an additional trigger to 121 
enhance the effect of ethanol on fibrosis development (29), lacking in other animal models, 122 
such as Lieber-deCarli, Tsukamoto-French or NIAAA (30, 31). Therefore, individual control 123 
groups (ethanol alone, CCl4 alone) were not used. The adaptation to alcohol included gradual 124 
increase and application of EtOH in drinking water starting from the low dose 1% at day 1 to 125 
maximum dose 10% at day 7. Therafter, animals were divided into 3 groups: 1. sham 126 
(sweetened drinking water) + vehicle (n=4); 2. EtOH + CCl4 + vehicle (n=8); 3. EtOH + 127 
CCl4 + MHK 5mg/kg/day (n=6). MHK was given by i.p. daily, for 5 weeks. As the effects of 128 
MHK on untreated animals on normal chow diet have been tested in (20), this control group 129 
was not included. At the end of the experiment (2 days after the last CCl4 injection) animals 130 
were sacrificed under isofluorane anesthesia by puncture of the right heart ventricle and 131 
exsanguination. Blood and liver tissue samples were either snap frozen or collected in 132 
formalin for further analyzes.  133 
 134 
Standard serum parameters 135 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in the 136 
internal laboratory of University Hospital Zürich, Institute of Clinical Chemistry.  137 
 138 
Liver histology, immunohistochemistry and morphometry  139 
Tissue samples were fixed in formalin and embedded in paraffin using routine histological 140 
procedures. Deparaffinized 4µm liver sections were stained with hematoxylin and eosin 141 
(H&E), and Sirius Red, according to the standard protocols and manufacturers’ 142 
recommendations. Alpha smooth muscle actine (αSMA) stain was performed using anti-143 
αSMA rabbit polyclonal antibody (Abcam; 1:200, overnight, +4°C) and detection performed 144 
with DAB Peroxidase (HRP) Substrate Kit (Dako, Denmark). 145 
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Morphometric quantification of Sirius Red staining was performed using an ImageJ 1.47t 146 
software system (32), and the results are presented as an area count, analysed from 5 fields 147 
per section (magnification 40x). Hepatic inflammation was evaluated semiquantitatively, 148 
based on the distribution of the inflammatory cells (1-4, single cells to multiple 149 
cells/islands/mild semi-confluent; 5-7, mild (semi-) confluent - moderate confluent; 8-10 150 
severe confluent). Hepatic necrosis was evaluated semiquantitatively, based on the following 151 
scoring system: 1 – single necrotic cells; 2 – semi-confluent (not connected bridges of 152 
necrotic cells between portal and/or central areas); 3 – confluent (connected bridges of 153 
necrotic cells between portal and/or central areas). All histological analyses were performed 154 
in blinded fashion.  155 
 156 
TaqMan PCR 157 
Total RNA was isolated from 30mg of liver tissue using the RNeasy kit (Qiagen, Basel, 158 
Switzerland), and cDNA was transcribed from 1µg of RNA using M-MLV reverse 159 
transcriptase (Invitrogen, Basel, Switzerland) with a random hexanucleotide mix (Roche, 160 
Basel, Switzerland). Quantitative real-time PCR was carried out on an ABI 7700 sequence 161 
detector (Applied Biosystems, Rotkreuz, Switzerland). All TaqMan probe and primer sets 162 
were obtained as ready-to-use kits from Applied Biosystems (Rotkreuz, Switzerland). For 163 
normalization the housekeeping gene GAPDH was amplified in a parallel reaction. 164 
 165 
Western blot analysis  166 
All devices, materials and reagents for western blotting were obtained from Thermo Fischer 167 
Scientific, Reinach, Switzerland, if not stated otherwise. Liver tissue protein extracts were 168 
prepared using T-PER® (Tissue Protein Extraction Reagent) containing CompleteTM protease 169 
inhibitor cocktail, Sample Reducing Agent BoltTM (10x), and LDS Sample Buffer BoltTM 170 
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(4x), according to manufacturers’ recommendations. 10µl (20µg) of lysates were applied to 171 
Bolt™ 4-12% or 12% Bis-Tris Plus gels transferred to iBlot™ 2 NC Regular Stacks using 172 
iBlot® 2 Dry Blotting System and stained with 0,5% Ponceau S to assure equal protein 173 
loading and transfer. Membranes were blocked and incubated with the primary antibody 174 
overnight at +4°C, incubated with the corresponding horseradish peroxidase-conjugated 175 
secondary antibody (Supplementary Table 1), and proteins detected using the 176 
WesternBrightTM Sirius western blotting detection kit (Advansta, CA, USA). For 177 
quantification analysis, all proteins of interest were normalized to GAPDH.  178 
 179 
Viability assay 180 
Cell viability was measured using Quick Cell Proliferation Assay Kit II (ab65475) (Abcam, 181 
Cambridge, UK), according to manufacturer’s recommendations.  182 
 183 
Quantification of ECs and related lipids with LC-MS/MS 184 
ECs, N-acetylethanolamines and arachidonic acid were measured in the liver by liquid 185 
chromatography tandem mass spectrometry (LC-MS), as described in Supporting 186 
Information.  187 
 188 
Statistics 189 
Comparison was performed with the one-way ANOVA Kruskal-Wallis test, or Mann-190 
Whitney U test, and survival was quantified with Kaplan-Meier analysis using the Graph Pad 191 
statistics software (Graph Pad Software Inc., San Diego, CA, USA). Results are given as 192 
means ± SD and considered statistically significant with a p-value <0.05.  193 
 194 
  195 
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RESULTS 196 
MHK improves hepatic fibrosis  197 
Five weeks of EtOH/CCl4 administration caused approximately 30% mortality, whereas 198 
MHK administration improved animal survival (Fig. 1A). Body, liver and spleen weights 199 
remained mainly unchanged after EtOH/CCl4 and MHK administration (not shown).  200 
Liver histology of fibrotic mice showed mild to moderate fibrosis with wide-spread 201 
proliferation of αSMA-positive portal myofibroblasts and HSC aligning fibrotic septas and 202 
necroinflammation areas (Fig. 1B). Morphometric analysis of Sirius Red staining 203 
demonstrated less pronounced extracellular matrix deposition after MHK treatment (Fig. 1C), 204 
as well as actin protein expression was similar to that in untreated healthy control mice (Fig. 205 
1D). Though no major changes were noticed at mRNA levels for PCα1, αSMA and TGFβ1 206 
by MHK, strongly upregulated MMP-2, -3, -9 and -13 levels were detected (Fig. 1E).  207 
 208 
MHK exerts mild anti-inflammatory effects in the liver 209 
Toxic injury in mice resulted in pronounced perilobular neutrophilic infiltration, aligning 210 
fibrotic septas and necrotic areas (Fig. 2A). Semi-quantitative evaluation revealed a reduced 211 
infiltration of immune cells upon MHK treatment (Fig. 2B), although at mRNA levels no 212 
major changes were detected, except of dramatic restoration of IFNγ. Although not 213 
statistically significant, TNFα mRNA was slighlty upregulated by MHK, whereas anti-214 
inflammatory IL-10 increased too (Fig. 2C).  215 
 216 
MHK protects from hepatocytes injury   217 
Administration of EtOH/CCl4 for 5 weeks resulted in moderate hepatotoxic injury, as 218 
evidenced by single cell decay or confluent areas of necrotic lesions from portal to central 219 
veins, or portal to portal areas (Fig. 3A). Semi-quantitative evaluation of necrotic areas 220 
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indicated that MHK seems to have a protective effect from toxic damage of alcohol and 221 
CCl4, although this did not reach statistical significance (Fig. 3A). However, serum liver 222 
enzymes and markers of liver damage ALT and AST were markedly elevated in alcoholic 223 
control group, and MHK significantly improved AST levels almost by 50% (Fig. 3B). 224 
Apoptosis-regulating bax, bak and bcl-xl proteins were not affected strongly neither in 225 
alcohol controls, nor by MHK treatment, however, a significant reduction of Mcl-1 and 226 
necrosis-regulating JNK1 was observed in the liver tissues from MHK group (Fig. 3C,D). 227 
Necroptosis-related RIPK1 was significantly downregulated in alcohol control group, 228 
whereas MHK normalized its expression back to normal levels (Fig. 3E). RIPK3 had similar 229 
tendency but not statistically significant. 230 
Alcohol-metabolising and oxidative stress producing enzymes CYP2E1, CYP4A14 and p47-231 
phox were not affected by MHK (Fig. 3F). 232 
    233 
MHK treatment increased hepatic AEA and related acetylethanomalides  234 
The levels of ECs anandamide (AEA) and 2-arachydonoilglycerol (2-AG), N-235 
acetlyethanolamines (NAEs) and arachidonic acid were measured in livers of all 236 
experimental groups. MHK treatment significantly increased by approximately 3-times the 237 
concentrations of AEA and the NAEs oleoylethanolamide (OEA), palmitoylethanolamide 238 
(PEA) and linolenoylethanolamine (LEA) including arachidonic acid (Fig. 4A). On the 239 
contrary, 2-AG levels were not affected by MHK treatment (Fig. 4A).  240 
The gene expression of some lipid metabolising enzymes was investigated in order to identify 241 
a possible cause for the increase of AEA and NAEs. Thus, MHK upregulated the expression 242 
of PPARγ and PNPLA3 mRNA compared with CCl4/EtOH treatment alone, and inhibited at 243 
the same time FAS and DGAT2 protein synthesis (Fig 4B,C). No major impact on the 244 
expression of SREBP1, MBOAT7 and ALDH1A1 was detected (Fig. 4B,C).                                   245 
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In parallel, the expression of CB1 and CB2 receptors and the major enzymes involved in 246 
AEA and 2-AG biosynthesis and degradation was evaluated. Interestingly, MHK abolished 247 
CB1 receptor overexpression, induced by hepatotoxins CCl4 and alcohol, whereas no 248 
statistically significant effects were detected on CB2, FAAH, MAGL, NAPE-PLD, PTPN22, 249 
DAGLβ and COX-2 mRNA expression (Fig. 4D). 250 
 251 
MHK reduced human HSC activation and induced apoptosis  252 
In vitro, human HSC were stimulated by TGFβ1 at 10ng/ml to induce profibrogenic 253 
phenotype, and when treated with MHK at 5-10µM, significant downregulation of PCα1(I), 254 
TGFβ1, αSMA, PDGFRβ, TNC, and TIMP1 was observed after the treatment for 24h with 255 
the highest concentration 10µM (Fig. 5A). At protein level, this was confirmed by HSC 256 
activation markers tenascin c and actin, which were reduced by MHK 10- and 2-fold, 257 
respectively (Fig. 5B).  258 
Cell viability was strikingly reduced by MHK at higher doses 10 and 20µM from 25 to 85%, 259 
respectively (Fig. 6A), paralleled by the 2-3-fold induction of bak1 and bcl2 mRNA at 10µM 260 
MHK (Fig. 6B).  261 
 262 
  263 
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DISCUSSION 264 
MHK is traditionally used in Chinese medicine for the therapy of depression and anxiety, and 265 
has been tested in experimental animal models of memory impairment or Alzheimer’s disease 266 
(14, 33-36). Although only a few studies investigated the effects of MHK in peripheral 267 
disorders, experimental data suggests a potential anti-tumor property of MHK in the 268 
treatment of oral squamous cell, prostate and colon carcinoma in vitro and in vivo (37-39). 269 
Other studies reported anti-inflammatory and anti-osteoclastogenic effects for MHK (40). 270 
Regarding liver diseases, only one study demonstrated that MHK may positively impact on 271 
features of the metabolic syndrome, such as obesity, insulin resistance and non-alcoholic 272 
steatohepatitis in a mouse high-fat-diet model (20). Considering the putative role of ECS in 273 
chronic liver diseases, we studied the effects of MHK in alcohol-induced liver damage in 274 
mice, and showed that it significantly reduces serum alanine and aspartate aminotransferases 275 
levels, significantly improves mice survival and alleviates liver fibrosis and damage via 276 
modulation of MMP-2, -3 and -13 and CB1 expression. The important role of matrix 277 
metalloproteinases degrading different types of collagens and other extracellular matrix 278 
proteins in fibrosis development is well established, and the particular anti-fibrotic role of 279 
MMP-2, -3 and -13 has been convincingly demonstrated (41). Even though the expression of 280 
the several key fibrogenic genes, such as PCα1, TGFβ1 and αSMA mRNA have not been 281 
found to be strongly affected by MHK in our animal model, the protein levels of actin were 282 
significantly less in MHK group, compared to fibrosis control, reflecting reduced HSC and 283 
myofibroblast number or activity. In addition, MMPs expression, activation, and thus, 284 
fibrolysis might be sufficient to shift the balance between fibrogenesis and fibrolyis towards 285 
fibrosis resolution. In vitro, MHK strikingly suppressed the expression of PCα1(I), actin, 286 
TGFβ1, TIMP1, tenascin, PDGFRβ and induced HSC apoptosis, confirming the direct anti-287 
fibrogenic efficacy of MHK on stellate cells and activated fibroblasts, which possibly could 288 
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be detected only at certain time points in vivo. The profibrogenic role of CB1 receptor has 289 
been repeatedly reported, and numerous investigators showed that genetic deletion or 290 
pharmacological antagonism of CB1 improves hepatic fibrosis, inflammation and liver fat 291 
accumulation in various experimental models (42). On the contrary, CB2 activation exerts 292 
anti-inflammatory and anti-fibrotic effects in liver and other organs (8, 10, 43). Interestingly, 293 
in our study, MHK did not affect the expression of CB2 receptor, but strongly abolished the 294 
CCl4/EtOH-induced upregulation of CB1, thus potentially leading to the inactivation of one 295 
of the major pro-fibrogenic pathways within the ECS network. 296 
Despite many studies providing evidence for a protective effect of MHK from 297 
neuroinflammation (13, 33, 36), the effect of MHK treatment on hepatic necroinflammation 298 
was only mild. Mice treated with MHK had slightly less neutrophilic infiltration in the 299 
periportal and pericentral areas of the liver. There was a trend towards improved levels of IL-300 
6, IFNγ and induced anti-inflammatory IL-10 mRNA by MHK, but these differences failed to 301 
reach statistical significance. Previous findings by others indicated that MHK may have an 302 
inhibitory effect on COX-2 (18, 44, 45), but again, this was not confirmed in experimental 303 
ALD, compatible with our findings of a lack of a striking effect on hepatic inflammation. 304 
When evaluating liver toxicity, we noticed that the premier type of hepatic cell death is 305 
necrosis and not apoptosis, as demonstrated by hepatocytes ballooning and disappearing 306 
nuclei. Therefore, to more specifically investigate the type of cell death the expression of 307 
genes coding for proteins involved in apoptosis, necrosis and necroptosis were evaluated. 308 
Although the necrotic lesions in the MHK group seem to be less striking, semiquantitative 309 
quantification did not reveal statistically significant difference with a control group. 310 
However, the levels of the liver function enzymes AST and ALT in the serum of mice 311 
receiving MHK showed a significant improval. In line with this observation, downregulation 312 
of necroptotic RIPK1 in alcohol-treated mice was restored by MHK to normal levels. RIPK1 313 
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had been shown to have a protective role, as RIPK1-/- mice die at birth, and rip-/- fibroblasts 314 
and thymocytes are sensitive to TNFα-induced cell death, as well as hematopoietic RIPK1 315 
deficiency triggers both apoptotic and necroptotic death  (46-48). This indicates that MHK 316 
either directly or indirectly stimulates RIPK1 signaling pathways pivotal for survival.  317 
No effects of MHK were found in the expression of proapoptotic bak, bax and bcl-xl 318 
proteins, whereas Mcl-1 and necrosis-mediating JNK1 were increased by EtOH/CCl4 319 
administration, and markedly decreased to normal levels with MHK treatment. All together, 320 
these data point to a protective potential of MHK in alcohol-mediated hepatic injury via the 321 
regulation of RIPK1, Mcl-1 and JNK signaling pathways.  322 
Reduction of oxidative damage by MHK in embryopathies induced by nicotine, as well as 323 
improved memory impairment by the same mechanism had been reported previously (34, 49-324 
51), and might partially explain the improvement of alcohol-induced liver damage in our 325 
study, which is also mediated by oxidative stress and free radical formation from alcohol-326 
induced cytochrome P450 2E1 (CYP2E1). However, the expression of CYP2E1, CYP4A14 327 
and p47-phox was not affected by MHK, indicating that MHK either influences other 328 
downstream proteins, or has a direct neutralizing effect on alcohol, CCl4 and related 329 
oxidative stress products. 330 
In livers from mice treated with MHK, levels of AEA and NAEs were increased by 331 
approximately three times compared with CCl4/EtOH, while 2-AG concentration was not 332 
affected. This difference seems to be associated with the distinc modulation of the expression 333 
of AEA and 2-AG degrading enzymes. MHK showed a clear trend towards lowering the 334 
expression of the main AEA and NAEs hydrolytic enzyme FAAH (although not being 335 
statistically significant), while it did not affect the 2-AG hydrolytic enzyme MAGL. None of 336 
the AEA, NAEs and 2-AG biosynthetic enzymes were modulated by MHK. This data suggest 337 
that the specific increase of AEA and NAEs levels over 2-AG may result, at least in part, 338 
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from a reduced degradation. AEA and NAEs are PPARs ligand and can potentially contribute 339 
to the MHK protective effect. In addition, reduced AEA hydrolysis limits the release of free 340 
arachidonic acid which is the main COX-2 substrate, thus ultimately leading to reduced 341 
formation of pro-inflammatory prostaglandins. 342 
To elucidate whether other lipid biosynthesic or degradating pathways were involved in AEA 343 
and NAEs increase, also keeping in mind potential pro-steatotic effects of CB2 activation, we 344 
measured the expression of genes coding for related enzymes and transcription factors 345 
pertinent for lipid turnover. We found that PPARγ and PNPLA3 mRNA expression was 346 
restored or induced by MHK, whereas SREBP1 and MBOAT7 were not affected neither by 347 
EtOH/CCl4 nor by MHK. This suggests a preponderance of lipid hydrolysis over synthesis, 348 
as also reflected by the downregulation of fatty acid synthase and diacylglycerol O-349 
acyltransferase 2 by MHK treatment in our model. In line with this observation, MHK was 350 
identified as a PPARγ agonist (38, 52), delivering an explanation for its potential anti-351 
steatotic functions, possibly via the insulin sensitizing and lipid lowering effects of 352 
PPARγ (20, 53).   353 
The relatively mild molecular effects of MHK in our model could be explained by the rapid 354 
degradation of MHK, as shown in vitro using rat liver microsomes and cytosol by Lee and 355 
coworkers, who demonstrated a high systemic plasma clearance and large volume of 356 
distribution, with an oral dose of 10 mg/kg resulting in a peak plasma concentration of only 357 
24.1±3.3 ng/ml at 3h and a low estimated bioavailability (54).  358 
Our study has some weaknesses related to the animal model used which produces only an 359 
incomplete pattern of ALD as encountered in humans. Rodents are notoriously resistant to the 360 
hepatotoxic effects of alcohol due to species-related differences, and rats or mice only 361 
develop fibrosis when exposed to alcohol in combination with a second toxin (e.g. carbon 362 
tetrachloride, thioacetamide) or major dietary manipulations (e.g. choline/methionine 363 
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deficiency) (31). In particular, our model produces little steatohepatitis, and lacks typical 364 
microscopic lesions such as Mallory-Denk bodies. However, our data demonstrate a 365 
protective effect of MHK on liver damage mediated by alcohol administration, resulting in 366 
reduced mortality, alleviated fibrosis and necroinflammation, possibly via direct antifibrotic 367 
effects and modulation of lipid metabolism. Though we expect similar effects in other models 368 
of alcohol-induced liver damage, further studies are necessary to understand whether the 369 
protective effects of MHK depend mainly on one pharmacological property (e.g. CB2 370 
activation) or are the consequence of polypharmacoloigcal actions in the ECS (e.g. CB2 371 
activation, limiting CB1 expression, increasing AEA and NAEs levels).  372 
  373 
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ABBREVIATIONS LIST 399 
AEA – N-arachidonoylethanolamine (anandamide) 400 
ALD – alcoholic liver disease 401 
ALDH1A1 - aldehyde dehydrogenase 1 family member A1 402 
ALT – alanine aminotransferase 403 
AST – aspart ataminotransferase 404 
2-AG – 2-Arachidonoylglycerol 405 
αSMA – alpha smooth muscle actin 406 
CB – cannabinoid receptor  407 
CCl4 – carbon tetrachloride 4 408 
CYP – cytochrome  409 
DGAT2 – diacylglycerol O-acyltransferase 2   410 
EC - endocannabinoid 411 
ECS – endocannabinoid system 412 
FAS – fatty acid synthase 413 
GAPDH – glyceraldehyde 3-phosphate dehydrogenase 414 
HFD – high-fat diet 415 
HSC – hepatic stellate cell 416 
IFNγ – interferon gamma 417 
IL – interleukin 418 
JNK – c-Jun N-terminal kinase 1 419 
LC-MS – liquid chromatography and mass spectrometry 420 
LEA – linolenoylethanolamine 421 
MBOAT7 - membrane bound O-acyltransferase domain containing 7 422 
Mcl-1 – myeloid leukemia cell differentiation protein – 1 423 
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MHK – methylhonokiol  424 
MMP – matrix metalloproteinase 425 
NAFLD – non-alcoholic fatty liver disease 426 
NAE - N-acetylethanolamine 427 
NE – noladin ether 428 
OEA – oleoylethanolamine 429 
PCα1 – procollagen alpha 1 (I) 430 
PEA – palmitoylethanolamide 431 
PPARγ − peroxisome proliferator-activated receptor gamma 432 
PNPLA3 – patatin-like phospholipase domain-containing protein 3 433 
RIPK – receptor interacting serine/threonine kinase  434 
SREBP1 – sterol regulatory element-binding protein-1 435 
TGFβ1 – transforming growth factor beta 1 436 
TNFα – tumor necrosis growth factor alpha 437 
438 
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FIGURE LEGENDS 599 
Figure 1. Survival, morphology and hepatic fibrosis after MHK treatment   600 
(A) Mice survival after 5 weeks of EtOH/CCl4 and MHK administration; (B) Representative 601 
liver sections of EtOH/CCl4 and EtOH/CCl4 + MHK (Sirius Red and αSMA IHC, 602 
magnification 10x). Moderate deposition of collagen fibers can be noticed in livers from 603 
fibrosis control group, whereas with MHK the severity of fibrotic matrix deposition is less 604 
pronounced. Strong positivity for αSMA differentiates activated myofibroblasts and HSC 605 
aligning fibrotic septas (brown); (C) Morphometric quantification of Sirius Red staining by 606 
ImageJ software from all experimental groups; (D) Actin protein expression levels measured 607 
by Western Blot and normalized to GAPDH; (E) Fibrosis-related mRNA expression, 608 
measured by TaqMan PCR and normalized to GAPDH (mean ± SD; *p<0.05, ns – non 609 
significant).   610 
      611 
Figure 2. MHK effect on hepatic inflammation  612 
(A) H&E staining and (B) semiquantitative evaluation of hepatic inflammation from 613 
EtOH/CCl4 and MHK groups. Mild to massive neutrophil infiltration can be noticed around 614 
necrotizing portal and central ares of the liver. (C) Inflammation-related mRNA expression, 615 
measured by TaqMan PCR and normalized to GAPDH (mean ± SD; *p<0.05, ns – non 616 
significant).   617 
 618 
Figure 3. MHK effect on hepatic necrosis  619 
(A) Representative example of typical necrotic lesions from H&E staining and semi-620 
quantitative analysis of necrotic areas, based on the severity and distribution of the necrotic 621 
cells. Aggregates of swelling hepatocytes with disappeared or empty nuclei and lost stain, 622 
indicating predominantly necrotic/necroptotic type of cell death vs apoptotic is clearly visible 623 
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on the section (yellow arrow, magnification 40x). (B) Serum liver enzymes ALT and AST 624 
(U/L) (mean ± SD; *p<0.05, ns – non significant). (C, D) Western blotting and corresponding 625 
quantification of apoptosis-regulating proteins bak, bax, bcl-xl, Mcl-1 and JNK1 using 626 
ImageJ software system. (E) Necroptosis-regulating kinases RIPK1 and RIPK3 mRNA, 627 
measured by TaqMan PCR and normalized to GAPDH (mean ± SD; *p<0.05, ns – non 628 
significant). (F) Alcohol-metabolizing and oxidative stress-related proteins measured by 629 
Western Blot and TaqMan PCR, normalized to GAPDH (mean ± SD; *p<0.05, ns – non 630 
significant).        631 
 632 
Figure 4. MHK effect on hepatic lipid metabolism  633 
(A) AEA, 2-AG  OEA, PEA, LEA and arachidonic acid (AA) levels in the liver (mean ± SD; 634 
***p<0.001, **p<0.01, *p<0.05). (B) PPARγ, SREBP1, PNPLA3 and MBOAT7 mRNA, 635 
measured by TaqMan PCR, normalized to GAPDH (mean ± SD; *p<0.05, ns – non 636 
significant). (C) Western blot and corresponding quantification of the bands of enzymes 637 
involved in lipid synthesis FAS, DGAT-2 and ALDH1A1 using ImageJ software system 638 
(mean ± SD; *p<0.05, ns – non significant). (D) ECS-related mRNA expression: cannabinoid 639 
receptors CB1 amd CB2, ECs degrading and metabolizing enzymes FAAH, MAGL and 640 
COX-2, ECs synthesizing enzymes NAPE-PLD, PTPN22 and DAGLβ, measured by 641 
TaqMan PCR and normalized to GAPDH (mean ± SD; *p<0.05, ns – non significant).    642 
 643 
Figure 5. MHK inhibited HSC activation 644 
(A) PCα1(I), αSMA, TGFβ1, PDGFRβ, TNC, IL-6, TIMP1, MMP-3 and MMP-13 mRNA 645 
expression in HSC activated by 10ng/ml TGFβ1, measured after 24h by TaqMan PCR and 646 
normalized to GAPDH (mean ± SD; *p<0.05, ns – non significant); (B) actin and tenascin 647 
protein expression in HSC activated by 10ng/ml TGFβ1, measured after 24h by Western 648 
Patsenker et al.                                                                                            MHK in alcohol-induced liver damage 
 26
Blot, analyzed by ImageJ and normalized to GAPDH (mean ± SD; *p<0.05, ns – non 649 
significant). 650 
Figure 6. MHK induced HSC apoptosis 651 
(A) HSC viability measured by WST assay after 24h of treatment with 10ng/ml TGFb1 and 652 
1-20µM MHK; (B) bak1, bax, Mcl-1, bcl2 and bcl-xl mRNA expression measured after 24h 653 
by TaqMan PCR and normalized to GAPDH (mean ± SD; *p<0.05, ns – non significant). 654 
 655 
 656 
      657 
 658 
